Summary
GlobalData's clinical trial report, “Vancomycin-Resistant Enterococcus faecium Infections Global Clinical Trials Review, H2, 2018" provides an overview of Vancomycin-Resistant Enterococcus faecium Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Vancomycin-Resistant Enterococcus faecium Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies Mentioned
LegoChem Biosciences Inc
Pfizer Inc
MicuRx Pharmaceuticals Inc
Worldwide Clinical Trials Holdings Inc
Hetero Drugs Ltd
Chr. Hansen Holding A/S
China Resources Group
AzurRx BioPharma Inc
Alvogen Inc
Allergan Plc
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Clinical Trials by G7 Countries: Proportion of Vancomycin-Resistant Enterococcus faecium Infections to Infectious Disease Clinical Trials 14
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Vancomycin-Resistant Enterococcus faecium Infections to Infectious Disease Clinical Trials 18
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials 30
Prominent Drugs 32
Clinical Trial Profile Snapshots 33
Appendix 54
Abbreviations 54
Definitions 54
Research Methodology 55
Secondary Research 55
About GlobalData 55
Contact Us 56
Source 56
List of Tables
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials by Region, 2018* 7
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 11
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Proportion of Vancomycin-Resistant Enterococcus faecium Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2018* 15
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
Proportion of Vancomycin-Resistant Enterococcus faecium Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2018* 19
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials by Phase, 2018* 21
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 22
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 31
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 32
List of Figures
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 11
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Proportion of Vancomycin-Resistant Enterococcus faecium Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2018* 14
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
Proportion of Vancomycin-Resistant Enterococcus faecium Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2018* 18
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials by Phase (%), 2018* 21
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 22
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 32
GlobalData Methodology 55
